Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | The Moffit experience of lenalidomide and rituximab for MCL

Bijal Shah, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, outlines the Moffitt experience of lenalidomide plus rituximab in TP53-mutated mantle cell lymphoma (MCL) outside of the clinical trial setting. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.